
-
What's not being discussed at G7 as Trump shapes agenda
-
UK apologises to thousands of grooming victims as it toughens law
-
Iran state TV briefly knocked off air by strike after missiles kill 11 in Israel
-
Trump urges Iran to talk as G7 looks for common ground
-
Canada wildfire near Vancouver contained
-
Four Atletico ultras get suspended jail for Vinicius effigy
-
England's top women's league to expand to 14 teams
-
Oil prices drop, stocks climb as Iran-Israel war fears ease
-
UN refugee agency says will shed 3,500 jobs due to funding cuts
-
US moves to protect all species of pangolin, world's most trafficked mammal
-
Kneecap 'unfazed' by legal problems, says friend and director
-
Electric fences, drones, dogs protect G7 leaders from bear attack
-
The name's Metreweli... Who is UK MI6's first woman chief?
-
Oil prices fall, stocks rise as Iran-Israel war fears ease
-
Fighter jets, refuelling aircraft, frigate: UK assets in Mideast
-
Iranian Nobel laureates, Cannes winner urge halt to Iran-Israel conflict
-
Struggling Gucci owner's shares soar over new CEO reports
-
Khamenei, Iran's political survivor, faces ultimate test
-
Ireland prepares to excavate 'mass grave' at mother and baby home
-
France shuts Israeli weapons booths at Paris Air Show
-
Iran and Israel exchange deadly strikes in spiralling air war
-
Ex-England captain Farrell rejoins Saracens from Racing 92
-
UN slashes global aid plan over 'deepest funding cuts ever'
-
Sri Lanka's Mathews hails 'dream run' in final Test against Bangladesh
-
Former England captain Farrell rejoins Saracens from Racing 92
-
Olympic champ Ingebrigtsen's father acquitted of abusing son
-
Maria climbs 43 places in WTA rankings after Queen's win
-
Iran hits Israel with deadly missile onslaught
-
German court jails Syrian 'torture' doctor for life
-
Oil prices fall even as Israel-Iran strikes extend into fourth day
-
Scientists track egret's 38-hour flight from Australia to PNG
-
Los Angeles curfew to continue for 'couple more days': mayor
-
Iran hits Tel Aviv after overnight Israeli strikes on Tehran
-
China factory output slows but consumption offers bright spot
-
G7 confronts Israel-Iran crisis as Trump dominates summit
-
Relatives wait for remains after Air India crash
-
China factory output slumps but consumption offers bright spot
-
Record-breaking Japan striker 'King Kazu' plays at 58
-
Trump lands in Canada as G7 confronts Israel-Iran crisis
-
Oil prices rise further as Israel-Iran extends into fourth day
-
Olympic champ Ingebrigtsen's father set for abuse trial verdict
-
German court to rule in case of Syrian 'torture' doctor
-
Trump orders deportation drive targeting Democratic cities
-
Spaun creates his magic moment to win first major at US Open
-
Royal Ascot battling 'headwinds' to secure foreign aces: racing director
-
Spaun wins US Open for first major title with late birdie binge
-
Israel pounds Iran, Tehran hits back with missiles
-
'Thin' chance against Chelsea but nothing to lose: LAFC's Lloris
-
PSG cruise over Atletico, Bayern thrash Auckland at Club World Cup
-
G7 protests hit Calgary with leaders far away

Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resume a regular quarterly investor call schedule, beginning with the release of its fiscal third quarter 2025 financial results in mid-August 2025. In alignment with this resumption, the Company has cancelled its previously scheduled intra-quarter investor call for June 17, 2025.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.
Visit adnas.com for more information. Follow us on X and LinkedIn.
Applied DNA Sciences Contact:
Investor Relations contact:
Sanjay M. Hurry, 917-733-5573, [email protected]
Web: https://investors.adnas.com/
SOURCE: Applied DNA Sciences
View the original press release on ACCESS Newswire
P.Stevenson--AMWN